The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Correction (v163,p1454)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Ilia, M.
* Articles by Price, J.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Ilia, M.
* Articles by Price, J.
Related Collections
* Schizophrenia Spectrum Disorders
* Genetics
* Molecular Biology
Am J Psychiatry 159:1174-1182, July 2002
© 2002 American Psychiatric Association


Article

Expression of Oct-6, a POU III Domain Transcription Factor, in Schizophrenia

Maria Ilia, B.Sc., Ph.D., Clare Beasley, B.Sc., Ph.D., Dies Meijer, Ph.D., Robert Kerwin, D.Sc., Ph.D., David Cotter, Ph.D., M.R.C.Psych., Ian Everall, Ph.D., M.R.C.Psych., and Jack Price, B.A., Ph.D.

OBJECTIVE: Oct-6, a POU-III domain transcription factor, is expressed in embryonic stem cells and Schwann cells and in neuronal subpopulations during early mammalian development, but its relevance to disorders of cerebral development in humans is untested. This study evaluated the expression of Oct-6 in schizophrenia, a disorder that has been linked with neurodevelopmental abnormalities. METHOD: Immunohistochemistry was used to examine Oct-6 expression in the temporal lobe in postmortem tissue from 10 subjects with schizophrenia and 10 matched comparison subjects. Western blot analysis was used to study Oct-6 expression in the frontal and temporal cortex in tissue from an additional three schizophrenic and three matched comparison subjects and in the frontal lobe only in tissue from an additional 10 schizophrenic and 10 matched comparison subjects. RESULTS: Extensive Oct-6 immunoreactivity was present in the temporal lobe in all 10 schizophrenic subjects, while very little or no expression was found in the comparison subjects. In schizophrenic subjects, Oct-6 immunoreactivity was found in a subset of cells in the pyramidal cell layer of the hippocampus and in the granule cell layer of the dentate gyrus. Oct-6 staining was predominantly localized in the cytoplasm. Western blot analysis confirmed the presence of Oct-6 in the frontal and temporal cortex in schizophrenic subjects but not in comparison subjects. CONCLUSIONS: The presence of Oct-6 expression in the schizophrenic subjects but not in the comparison subjects suggests that Oct-6 may provide a marker for the neuropathology associated with schizophrenia. Further, it may provide a clue to the neurodevelopmental basis of the disease and could be a reliable means to examine the developmental brain abnormalities described in this disorder.




This article has been cited by other articles:


Home page
Genes Dev.Home page
M. Jaegle, M. Ghazvini, W. Mandemakers, M. Piirsoo, S. Driegen, F. Levavasseur, S. Raghoenath, F. Grosveld, and D. Meijer
The POU proteins Brn-2 and Oct-6 share important functions in Schwann cell development
Genes & Dev., June 1, 2003; 17(11): 1380 - 1391.
[Abstract] [Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org